FUKOKU MUTUAL LIFE INSURANCE Co Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

FUKOKU MUTUAL LIFE INSURANCE Co grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 25.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,522 shares of the medical research company’s stock after acquiring an additional 305 shares during the quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in IQVIA were worth $299,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new position in IQVIA in the third quarter worth $27,000. Synergy Asset Management LLC purchased a new stake in IQVIA during the fourth quarter worth $33,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. raised its position in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in IQVIA in the 3rd quarter worth about $57,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IQV. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. UBS Group lowered their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Stephens began coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Finally, TD Cowen lowered their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Stock Performance

IQVIA stock opened at $190.77 on Thursday. The firm has a market capitalization of $33.59 billion, a P/E ratio of 25.44, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The stock has a fifty day moving average price of $199.40 and a two-hundred day moving average price of $215.46.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Transactions at IQVIA

In related news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.